https://orcid.org/0000-0001-6652-3275
References
- Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia. 2013;27(3):553–559. doi:10.1038/leu.2012.290
- Zwicker JI, Wang TF, DeAngelo DJ, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost. 2020;18(2):278–284. doi:10.1111/jth.14671
- Pui CH, Jackson CW, Chesney C, et al. Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine. J Clin Oncol. 1983;1(6):380–385. doi:10.1200/JCO.1983.1.6.380
- Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol. 1987;5(5):811–817. doi:10.1200/JCO.1987.5.5.811
- Priest JR, Ramsay NK, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 1982;100(6):990–995. doi:10.1016/S0022-3476(82)80536-2
- Ramsay NK, Coccia PF, Krivit W, Nesbit ME, Edson JR. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer. 1977;40(4):1398–1401.
- Bezeaud A, Drouet L, Leverger G, Griffin JH, Guillin MC. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr. 1986;108(5 Pt 1):698–701. doi:10.1016/S0022-3476(86)81044-7
- Bettigole RE, Himelstein ES, Oettgen HF, Clifford GO. Hypofibrinogenemia due to L-asparaginase: studies of fibrinogen survival using autologous 131-I-fibrinogen. Blood. 1970;35(2):195–200. doi:10.1182/blood.V35.2.195.195
- Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest. 1988;18(5):512–516. doi:10.1111/j.1365-2362.1988.tb01049.x
- Goyal G, Bhatt VR. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia. Fut Oncol. 2015;11(17):2459–2470. doi:10.2217/fon.15.114
- Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767. doi:10.1182/blood-2005-04-1623
- Orvain C, Balsat M, Tavernier E, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020;136(3):328–338. doi:10.1182/blood.2020004919
- Wheeler K, Chessells JM, Bailey CC, Richards SM. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child. 1996;74(2):101–107. doi:10.1136/adc.74.2.101
- Ben Mautner EP, Mort J, DiBenedetto S, et al. The risks of thrombotic and bleeding events in patients receiving PEGylated asparaginase for treatment of acute lymphoblastic leukemia. J Clin Oncol. 2022;40(16):e19015.
- Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375–380. doi:10.1111/ejh.12600
- Lejhancova-Tousovska K, Zapletal O, Vytiskova S, Strbackova P, Sterba J. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Munster (BFM) protocols. Blood Coagul Fibrinolysis. 2012;23(2):144–154. doi:10.1097/MBC.0b013e32834fb539
- Yamaguchi M et al . (2011). Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell tumor study group study. J Clin Oncol, 29(33), 4410–6. 10.1200/JCO.2011.35.6287